These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25672931)

  • 1. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease.
    McIntyre JA; Ramsey CJ; Gitter BD; Saykin AJ; Wagenknecht DR; Hyslop PA;
    Autoimmunity; 2015; 48(5):344-51. PubMed ID: 25672931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox-reactive antiphospholipid antibody differences between serum from Alzheimer's patients and age-matched controls.
    McIntyre JA; Wagenknecht DR; Ramsey CJ
    Autoimmunity; 2009; 42(8):646-52. PubMed ID: 19886736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies.
    McIntyre JA; Chapman J; Shavit E; Hamilton RL; Dekosky ST
    Autoimmunity; 2007 Jul; 40(5):390-6. PubMed ID: 17612901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
    Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
    J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
    Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
    J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
    Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
    Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.
    Williams SM; Schulz P; Rosenberry TL; Caselli RJ; Sierks MR
    J Alzheimers Dis; 2017; 58(1):23-35. PubMed ID: 28372328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of multiple autoantibodies is associated with the risk of Alzheimer's disease and cognitive impairment.
    Shim SM; Koh YH; Kim JH; Jeon JP
    Sci Rep; 2022 Jan; 12(1):1312. PubMed ID: 35079008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia.
    Kulczyńska-Przybik A; Słowik A; Mroczko P; Borawski B; Groblewska M; Borawska R; Mroczko B
    Curr Alzheimer Res; 2020; 17(8):709-721. PubMed ID: 33167838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study.
    Lim B; Sando SB; Grøntvedt GR; Bråthen G; Diamandis EP
    Neurobiol Aging; 2020 Sep; 93():97.e1-97.e7. PubMed ID: 32362369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.